Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 285Lymphoma 201Lymphoma, Large B-Cell, Diffuse 167Sarcoma 141Precursor Cell Lymphoblastic Leukemia-Lymphoma 109Hodgkin Disease 85Lymphoma, Non-Hodgkin 78Burkitt Lymphoma 67Lymphoma, Follicular 61Leukemia 58Ovarian Neoplasms 50Neoplasms 50Triple Negative Breast Neoplasms 49Lymphoma, Mantle-Cell 48Multiple Myeloma 47Neuroblastoma 44Carcinoma, Hepatocellular 44Neoplasm Metastasis 41Lymphoma, B-Cell 33Lymphoma, Large-Cell, Anaplastic 31Lymphoma, T-Cell, Peripheral 27Recurrence 26Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 25Osteosarcoma 25Liposarcoma 25Leiomyosarcoma 25Urinary Bladder Neoplasms 23Lymphoma, Large-Cell, Immunoblastic 23Liver Neoplasms 22Endometrial Neoplasms 21

Interventions

Triptorelin Pamoate 1Paclitaxel 1Fulvestrant 1Doxorubicin 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × The Neoadjuvant Therapy × Doxorubicin × Clear all
NCT04753177 2021-02-15

The Neoadjuvant Combined Hormone Therapy in Premenopausal Women With Locally Advanced ER+/HER2- Breast Cancer

Saint Petersburg State Budgetary Healthcare Institution, City Clinical Oncology Dispensary

Phase 2/3 Unknown
120 enrolled

The Neoadjuvant Therapy

Data powered by HemOnc (CC BY 4.0) Colophon âš¡